On Invalid Date, Novo Nordisk A S (NYSE: NVO) reported Q4 2023 earnings per share (EPS) of $0.73, up 67.59% year over year. Total Novo Nordisk A S earnings for the quarter were $3.25 billion. In the same quarter last year, Novo Nordisk A S's earnings per share (EPS) was $0.44.
As of Q2 2024, Novo Nordisk A S's earnings has grown 56.54% year over year. This is 4.16 percentage points higher than the US Biotechnology industry earnings growth rate of 52.38%. Novo Nordisk A S's earnings in the past year totalled $12.18 billion.
What is NVO's earnings date?
Novo Nordisk A S's earnings date is Invalid Date. Add NVO to your watchlist to be reminded of NVO's next earnings announcement.
What was NVO's revenue last quarter?
On Invalid Date, Novo Nordisk A S (NYSE: NVO) reported Q4 2023 revenue of $9.76 billion up 40.81% year over year. In the same quarter last year, Novo Nordisk A S's revenue was $6.93 billion.
What was NVO's revenue growth in the past year?
As of Q2 2024, Novo Nordisk A S's revenue has grown 34.95% year over year. This is 116.51 percentage points lower than the US Biotechnology industry revenue growth rate of 151.46%. Novo Nordisk A S's revenue in the past year totalled $33.81 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.